A Phase II, Open-Label, Study of Subcutaneous Canakinumab, an Anti-IL-1β Human Monoclonal Antibody, for Patients With Low or Int-1 Risk IPSS/IPSS-R Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia

Clinical trial NCT04239157 · RECRUITING

Trial details

NCT number: NCT04239157
Sponsor: M.D. Anderson Cancer Center
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Chronic Myelomonocytic Leukemia Myelodysplastic Syndrome Recurrent Chronic Myelomonocytic Leukemia Recurrent Myelodysplastic Syndrome Refractory Chronic Myelomonocytic Leukemia Refractory Myelodysplastic Syndrome

Start date: 2020-08-25
Primary completion: 2026-12-31
Enrollment: 76

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.